Link Medical

Executive Summary

Link Medical is a Nordic Contract Research Organization (CRO) and regulatory service provider headquartered in Oslo, Norway. Founded in 2005, the company offers comprehensive product development services from concept through commercialization, specializing in oncology, rare diseases, and neuroscience. With a strong Nordic culture of integrity and agility, Link Medical serves pharmaceutical, biotechnology, and medical device/IVD companies, leveraging deep therapeutic expertise to accelerate clinical programs. The company is privately held, employs 51-200 people, and operates at Phase 2 stage, indicating active involvement in mid-stage clinical trials. Despite limited public data, its niche focus on complex therapeutic areas positions it as a specialized partner in the CRO market, particularly for Nordic and European clients. Link Medical's business model benefits from the growing outsourcing trend in drug development, especially in oncology and rare diseases where specialized knowledge is critical. The company's agility and size allow for personalized service, competing with larger CROs. However, as a private company, financial details are undisclosed, and its growth trajectory depends on client acquisition and successful project delivery. Key risks include dependence on client funding cycles and regulatory changes. Overall, Link Medical appears well-positioned in a stable niche, but its limited scale may constrain rapid growth. The conviction score reflects moderate confidence in its near-term performance, given the lack of transparent metrics.

Upcoming Catalysts (preview)

• Q3 2026Major contract win with a top-20 pharmaceutical company for a late-stage oncology trial60% success
• Q2 2026Expansion into gene therapy clinical services through strategic partnership or acquisition50% success
• Q4 2026First FDA or EMA approval of a client drug where Link Medical provided lead CRO services40% success